Research and Markets: Global Bone Metastasis Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/hb2nwj/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Ablynx NV
  • Aegera Therapeutics Inc.
  • Alethia Biotherapeutics Inc.
  • Amgen Inc.
  • Amura Holdings Limited
  • Bayer AG
  • ChemoCentryx, Inc.
  • Debiopharm International S.A.
  • Deciphera Pharmaceuticals, LLC
  • Digna Biotech, S.L.
  • Kyowa Hakko Kirin Co., Ltd.
  • Medivir AB
  • Merrion Pharmaceuticals Plc
  • Oncobiologics, Inc.
  • Oncodrone BV
  • Osteologix Holdings Plc
  • R-Pharm
  • Sigma-Tau S.p.A.
  • Terpenoid Therapeutics, Inc.
  • Thar Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/hb2nwj/bone_metastasis.

Contacts:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.